More Significant Drug Price Cuts

BMI View: Public regulatory bodies in emerging markets will become increasingly involved in reducing the prices of pharmaceuticals. Multinational drugmakers are looking to offset fiscal austerity measures and stagnant sales growth in Europe and the US by moving into the emerging markets. However, price control measures will eventually follow them from the developed markets. Drugmakers should increase their use of pharmacoeconomics to prove the value of their products when negotiating drug price tenders. This could be the beginning of the end for the practice of pricing drugs at the maximum a market can

To read the full article, please choose one of the following options: